Antigenic constructs of major histocompatibility complex class I antigens with specific carrier molecules, the preparation and use thereof

Abstract

Antigenic constructs which result from linkage of major histocompatibility complex (MHC) class I antigens with specific carrier molecules are described. The linkage is effected N- or C-terminally by covalent bonding or, in the case of non-covalent bonding, for example by an avidin/biotin bridge. The specific carrier molecules bind selectively to target cells and are preferably monoclonal antibodies. Processes of genetic manipulation for the preparation of such constructs are indicated. Antigenic constructs according to the invention are used to damage or eliminate target cells.

1 . Antigenic constructs in which major histocompatibility complex (MHC) class I antigens are linked at the C- or N-terminal end to specific carrier molecules.  
     
     
         2 . Antigenic constructs in which major histocompatibility complex (MHC) class I antigens are linked at the amino-terminal end to specific carrier molecules.  
     
     
         3 . Antigenic constructs in which major histocompatibility complex (MHC) class I antigens are linked at the C-terminal end to specific carrier molecules.  
     
     
         4 . Antigenic constructs as claimed in  claim 1 , in which one MHC class I antigen is linked to one specific carrier molecule respectively.  
     
     
         5 . Antigenic constructs as claimed in  claim 1 , in which the specific carrier molecules are CD4 domains.  
     
     
         6 . Antigenic constructs as claimed in  claim 1 , in which the specific carrier molecules are monoclonal antibodies.  
     
     
         7 . Antigenic constructs as claimed in  claim 6 , in which the monoclonal antibodies are shortened in the constant part of the heavy chain.  
     
     
         8 . Antigenic constructs as claimed in  claim 1 , in which the MHC class I antigen is HLA B27w or HLA B27k.  
     
     
         9 . Antigenic constructs as claimed in  claim 1 , in which the MHC class I antigen is covalently bonded to the carrier molecule.  
     
     
         10 . Antigenic constructs as claimed in  claim 1 , in which the MHC class I antigen is bonded via avidin/biotin to the carrier molecule.  
     
     
         11 . Antigenic constructs as claimed in  claim 1 , which are prepared by genetic manipulation by fusion of the DNAs coding for them.  
     
     
         12 . A process for the preparation of antigenic constructs as claimed in  claim 1 , which comprises the required parts of genes being fused in the form of their DNA, being provided with suitable regulation sequences and being expressed in suitable expression systems.  
     
     
         13 . The use of the antigenic constructs as claimed in  claim 1  for the allogenization of target cells.  
     
     
         14 . A pharmaceutical which contains antigenic constructs as claimed in  claim 1.